Search

Sarepta Therapeutics Statement on April 26, 2021 ICER Commentary Regarding the Accelerated Approval Pathway
Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)